Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (5728)	1/7/1999 12:42:00 AM
From: BRAVEHEART	Respond to of 90042

SPEAKING OF SUMMARIES: LXR Hi Gang, I consider LXR another extremely undervalued Biotech. The stock traded between two and four much of the past year until the market crash in Aug. It then suffered like most of biotech. The company has not rebounded yet for one primary reason. The company has been making the transition from a primary R&D stage biotech to it's present form as a product development stage biotech. This included a massive change of the board. I now believe LXR is poised to rebound to the highs of 1998. Especially once it fully collaborates it's three primary compounds and advances them into clinicals. This board change resulted in the hiring of a new CEO, Paul Hastings. Paul has the background experience to see LXR through it's many hurdles in becoming a successful enterprise. Especially now that LXR has entered the product phase of development. "Genzyme Corporation (1994 to 1998) Vice President Global Marketing, President Genzyme Therapeutics Europe, President Genzyme Therapeutics. Synergen, Inc. (1989 to 1994) Vice President, Marketing and Sales, and Vice President, General Manager, Synergen Europe, Inc. Hoffman La Roche (1984 to 1989) various marketing and sales management positions" The company has an attractive product line. Including the following. HK-CardiosolTM - Heart protectant solution for transplantation. CP-CardiosolTM - Improved organ protection during heart/lung bypass operations. ElirexTM - Drug for inhibition of heart damage following heart attack. A few of the recent press releases suggest the potential of these products: CP-Cardiosol- lxr.com "LXR initiated the preclinical study in October 1998, and has plans to complete all the requested studies by early next year, at which time it plans to submit an amendment to the IND. Although these CP-Cardiosol(TM) heart bypass trials would be the first bypass trials run by LXR, an earlier formulation of CP-Cardiosol(TM) was used in a 95-patient study done by the California Pacific Medical Center. In that study, Cardiosol(TM) showed clear superiority to control hearts. The Cardiosol treated patients had stronger heart function (cardiac output), 72% returned to normal heart beat versus 5% of the control group, and required less inotropic (heart stimulating) support to maintain heart function following the surgery." This Study should be available right about now... : ) Elirex: lxr.com This compound has major implications for the company both short term & long term. "In in vitro studies for the protection of cultured cells, including heart muscle cells, the new compound was 10 to 100 times more potent than the original Elirex™ compound. In addition, its chemical composition is much simpler and it is anticipated to be more stable in the body." Initially I look forward to learning more on what added potential this compound has as far as treatment indications go. Plausibly it could result in additional markets over and above prior expectations which already targeted billion dollar markets. In reality these are the kind of products which attract corporate collaborations. Hence this translates into added shareholder value. Alone the original Elerix compound the company is currently advancing has considerable potential already. Estimates suggest the targeted market is of blockbuster proportions. The market size is projected to be a billion plus. This is a market with a known size with unmet needs. The investor interest should be intense as the product advances through clinicals. "Elirex™ has been the subject of promising preclinical heart attack studies at The Cleveland Clinic, Emory University and the University of California at San Francisco." "In the Cleveland Clinic study, conducted under the guidance of Drs. Eric Topol, Francesca Nicolini and Mitchell Silver, Elirex™ reduced the amount of damage to test animals' hearts by an average of 53% over controls. The results of this study were presented in March 1998 at The Cleveland Clinic Symposium on Myocardial Reperfusion and at the American College of Cardiology's Scientific Section." This new analog may offer even greater potential to enter other markets with the compound because of it's characteristics. I look forward to preclinical test results as they become available. "The Company plans to initiate preclinical studies of the new compound in an animal heart attack model at the University of California at San Francisco shortly. In addition, the Company plans to begin a preclinical study of this compound for the protection of neuronal cells from ischemic damage." Continued R&D with Apoptosis lxr.com "Discovered by LXR scientists in 1993, the Bak gene is known to be a potent inducer of apoptotic cell death and is believed to be important in regulating physiologic cell turnover in a number of organ systems. In addition, Bak is down-regulated in a number of tumor types, including colon cancer." This bit of patented rights alone can go a long way in R&D for a variety of indications resulting in all sorts of collaborations. The company has approx 28,000,000 shares outstanding. Of which approximately 55% are closely held by insiders and institutions. Important to this understanding is the fact that many key individuals hold large positions in the company. Not remote foreign & junk funds. In fact over approximately the past year two prominent insiders made large purchases of greater than 500,000 shares at $1.75. One was none other than William Hambrecht. Who joined on as a member of the board last spring. INSIDER BUYING: biz.yahoo.com TECHNICALS: I have followed LXR for close to 18 months. I called the last breakout last spring in Mar/Apr. The stock traded from 1.75 or so to four. In a solid range for an extended period of time. Not some spike. I again believe LXR is poised to trade back into that same range. The technicals displayed a pattern around Dec 1st. Check Yahoo message threads on both periods. Now check the charts. clearstation.com. With a series of collaborations of it's three primary products and LXR will possibly exceed my expectations over the near term. I have great expectations for LXR over the next year. The company has several products with considerable promise. LXR's compounds include HK-Cardiosol™, a heart protective solution for heart transplant; CP-Cardiosol™, a cardioplegia solution for bypass surgery; and Elirex™. I would imagine we can anticipate a series of announcements related to the progression of these compounds over the course time. THE TRUTH IS OUT THERE LONE WOLF